{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T07:58:54Z","timestamp":1789718334181,"version":"4.0.1"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.addr.2016.02.001","type":"journal-article","created":{"date-parts":[[2016,2,12]],"date-time":"2016-02-12T04:46:12Z","timestamp":1455252372000},"page":"62-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"special_numbering":"C","title":["When barriers ignore the \u201crule-of-five\u201d"],"prefix":"10.1016","volume":"101","author":[{"given":"Stefanie D.","family":"Kr\u00e4mer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne E.","family":"Aschmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Hatibovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina F.","family":"Hermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia S.","family":"Neuhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrill","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Belli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2016.02.001_bb0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2016.02.001_bb0010","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1039\/c1md00093d","article-title":"Intramolecular hydrogen bonding to improve membrane permeability and absorption in beyond rule of five chemical space","volume":"2","author":"Alex","year":"2011","journal-title":"Med. Chem. Comm."},{"key":"10.1016\/j.addr.2016.02.001_bb0015","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.chembiol.2014.08.013","article-title":"Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates","volume":"21","author":"Doak","year":"2014","journal-title":"Chem. Biol."},{"key":"10.1016\/j.addr.2016.02.001_bb0020","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.5b00586","article-title":"New frontiers in druggability","author":"Kozakov","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2016.02.001_bb0025","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2165\/00003088-200241110-00005","article-title":"Theoretical predictions of drug absorption in drug discovery and development","volume":"41","author":"Stenberg","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.addr.2016.02.001_bb0030","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1021\/mp400713v","article-title":"Passive lipoidal diffusion and carrier-mediated cell uptake are both important mechanisms of membrane permeation in drug disposition","volume":"11","author":"Smith","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2016.02.001_bb0035","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.drudis.2012.03.015","article-title":"Evidence-based approach to assess passive diffusion and carrier-mediated drug transport","volume":"17","author":"Di","year":"2012","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.addr.2016.02.001_bb0040","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijpharm.2009.02.002","article-title":"Theoretical investigation of passive intestinal membrane permeability using Monte Carlo method to generate drug-like molecule population","volume":"373","author":"Sugano","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2016.02.001_bb0045","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s10545-013-9608-0","article-title":"Blood\u2013brain barrier structure and function and the challenges for CNS drug delivery","volume":"36","author":"Abbott","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.addr.2016.02.001_bb0050","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.drudis.2012.11.008","article-title":"The promiscuous binding of pharmaceutical drugs and their transporter-mediated uptake into cells: what we (need to) know and how we can do so","volume":"18","author":"Kell","year":"2013","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.addr.2016.02.001_bb0055","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrd3187","article-title":"Coexistence of passive and carrier-mediated processes in drug transport","volume":"9","author":"Sugano","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2016.02.001_bb0060","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.addr.2012.09.042","article-title":"Intestinal drug transporters: an overview","volume":"65","author":"Estudante","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2016.02.001_bb0065","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1517\/17425247.2012.697055","article-title":"Targeted prodrugs in oral drug delivery: the modern molecular biopharmaceutical approach","volume":"9","author":"Dahan","year":"2012","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2016.02.001_bb0070","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2174\/13816128113199990462","article-title":"Role of monocarboxylate transporters in drug delivery to the brain","volume":"20","author":"Vijay","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.addr.2016.02.001_bb0075","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.coph.2013.09.001","article-title":"OATP transporter-mediated drug absorption and interaction","volume":"13","author":"Tamai","year":"2013","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.addr.2016.02.001_bb0080","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1517\/17460441.2014.922540","article-title":"In vitro and in vivo approaches to characterize transporter-mediated disposition in drug discovery","volume":"9","author":"Feng","year":"2014","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.addr.2016.02.001_bb0085","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.mam.2012.11.003","article-title":"Proton-coupled oligopeptide transporter family SLC15: physiological, pharmacological and pathological implications","volume":"34","author":"Smith","year":"2013","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.addr.2016.02.001_bb0090","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/tpj.2015.78","article-title":"Role of SLC22A1 polymorphic variants in drug disposition, therapeutic responses, and drug\u2013drug interactions","volume":"15","author":"Arimany-Nardi","year":"2015","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.addr.2016.02.001_bb0095","series-title":"Enzyme- and Transporter-Based Drug\u2013Drug Interactions: Progress and Future Challenges","article-title":"Transporters: Importance in Drug Absorption, Distribution, and Removal","author":"Russel","year":"2010"},{"key":"10.1016\/j.addr.2016.02.001_bb0100","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.coph.2013.08.010","article-title":"Clinical relevance of drug efflux pumps in the gut","volume":"13","author":"Misaka","year":"2013","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.addr.2016.02.001_bb0105","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1042\/bse0500161","article-title":"The P-glycoprotein multidrug transporter","volume":"50","author":"Sharom","year":"2011","journal-title":"Essays Biochem."},{"key":"10.1016\/j.addr.2016.02.001_bb0110","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1208\/s12248-014-9668-6","article-title":"Role of the breast cancer resistance protein (BCRP\/ABCG2) in drug transport\u2014an update","volume":"17","author":"Mao","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.addr.2016.02.001_bb0115","doi-asserted-by":"crossref","first-page":"E118","DOI":"10.1208\/aapsj070112","article-title":"Role of the breast cancer resistance protein (ABCG2) in drug transport","volume":"7","author":"Mao","year":"2005","journal-title":"AAPS J."},{"key":"10.1016\/j.addr.2016.02.001_bb0120","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/clpt.2011.108","article-title":"Nonlinear pharmacokinetics of oral quinidine and verapamil in healthy subjects: a clinical microdosing study","volume":"90","author":"Maeda","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2016.02.001_bb0125","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.tips.2015.02.009","article-title":"Quantifying the impact of transporters on cellular drug permeability","volume":"36","author":"Matsson","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.addr.2016.02.001_bb0130","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1021\/js980378j","article-title":"Role of P-glycoprotein-mediated secretion in absorptive drug permeability: an approach using passive membrane permeability and affinity to P-glycoprotein","volume":"88","author":"Doppenschmitt","year":"1999","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2016.02.001_bb0135","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/j.bcp.2013.02.021","article-title":"PK\/PD assessment in CNS drug discovery: prediction of CSF concentration in rodents for P-glycoprotein substrates and application to in vivo potency estimation","volume":"85","author":"Caruso","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.addr.2016.02.001_bb0140","article-title":"Quantitative aspects of drug permeation across in vitro and in vivo barriers","author":"Kr\u00e4mer","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2016.02.001_bb0145","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1021\/mp0500871","article-title":"P-glycoprotein recognition of substrates and circumvention through rational drug design","volume":"3","author":"Raub","year":"2006","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2016.02.001_bb0150","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1007\/s11095-014-1431-2","article-title":"Cell-free microfluidic determination of P-glycoprotein interactions with substrates and inhibitors","volume":"31","author":"Eyer","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2016.02.001_bb0155","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nchem.1243","article-title":"Quantifying the chemical beauty of drugs","volume":"4","author":"Bickerton","year":"2012","journal-title":"Nat. Chem."},{"key":"10.1016\/j.addr.2016.02.001_bb0160","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1021\/ci300010y","article-title":"Use of 3D properties to characterize beyond rule-of-5 property space for passive permeation","volume":"52","author":"Guimaraes","year":"2012","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.addr.2016.02.001_bb0165","unstructured":"NCBI, PubChem, http:\/\/pubchem.ncbi.nlm.nih.gov."},{"key":"10.1016\/j.addr.2016.02.001_bb0170","unstructured":"FDA, StructuredProductLabeling (SPL), http:\/\/www.fda.gov\/ForIndustry\/DataStandards\/StructuredProductLabeling."},{"key":"10.1016\/j.addr.2016.02.001_bb0175","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/B978-0-12-800223-0.00004-9","article-title":"Biology of the major facilitative folate transporters SLC19A1 and SLC46A1","volume":"73","author":"Hou","year":"2014","journal-title":"Curr. Top. Membr."},{"key":"10.1016\/j.addr.2016.02.001_bb0180","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1146\/annurev-physiol-020911-153251","article-title":"The intestinal absorption of folates","volume":"76","author":"Visentin","year":"2014","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.addr.2016.02.001_bb0185","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.3109\/00498254.2014.920551","article-title":"Characterization of gastrointestinal absorption of digoxin involving influx and efflux transporter in rats: application of mdr1a knockout (\u2212\/\u2212) rats into absorption study of multiple transporter substrate","volume":"44","author":"Suzuki","year":"2014","journal-title":"Xenobiotica"},{"key":"10.1016\/j.addr.2016.02.001_bb0190","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jconrel.2013.10.037","article-title":"A liposomal fluorescence assay to study permeation kinetics of drug-like weak bases across the lipid bilayer","volume":"173","author":"Eyer","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2016.02.001_bb0195","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1128\/AAC.42.10.2626","article-title":"Rifampin concentrations in various compartments of the human brain: a novel method for determining drug levels in the cerebral extracellular space","volume":"42","author":"Mindermann","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2016.02.001_bb0200","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0009-9120(95)02024-1","article-title":"In vitro protein binding characteristics of isoniazid, rifampicin, and pyrazinamide to whole plasma, albumin, and alpha-1-acid glycoprotein","volume":"29","author":"Woo","year":"1996","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.addr.2016.02.001_bb0205","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1021\/mp049937n","article-title":"Evidence of efflux-mediated and saturable absorption of rifampicin in rat intestine using the ligated loop and everted gut sac techniques","volume":"1","author":"Mariappan","year":"2004","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2016.02.001_bb0210","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejps.2013.01.017","article-title":"Effect of repeated dosing on rifampin exposure in BALB\/c mice","volume":"49","author":"Hosagrahara","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2016.02.001_bb0215","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1073\/pnas.93.9.4001","article-title":"P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans","volume":"93","author":"Schuetz","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2016.02.001_bb0220","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1021\/jm100087s","article-title":"Intramolecular hydrogen bonding in medicinal chemistry","volume":"53","author":"Kuhn","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2016.02.001_bb0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbamem.2005.07.009","article-title":"Behaviour of small solutes and large drugs in a lipid bilayer from computer simulations","volume":"1718","author":"Bemporad","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.addr.2016.02.001_bb0230","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.bbamem.2014.01.006","article-title":"The basic structure and dynamics of cell membranes: an update of the singer-Nicolson model","volume":"1838","author":"Goni","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.addr.2016.02.001_bb0235","doi-asserted-by":"crossref","first-page":"9391","DOI":"10.1021\/jp510497r","article-title":"Effects of cholesterol on the thermodynamics and kinetics of passive transport of water through lipid membranes","volume":"119","author":"Issack","year":"2015","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.addr.2016.02.001_bb0240","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1016\/S0006-3495(03)74768-7","article-title":"Permeation across hydrated DPPC lipid bilayers: simulation of the titrable amphiphilic drug valproic acid","volume":"85","author":"Ulander","year":"2003","journal-title":"Biophys. J."},{"key":"10.1016\/j.addr.2016.02.001_bb0245","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1021\/ct400738r","article-title":"Transmembrane permeation mechanism of charged methyl guanidine","volume":"10","author":"Wang","year":"2014","journal-title":"J. Chem. Theory Comput."},{"key":"10.1016\/j.addr.2016.02.001_bb0250","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0006-3495(97)78118-9","article-title":"Water permeability of polyunsaturated lipid membranes measured by 17O NMR","volume":"73","author":"Huster","year":"1997","journal-title":"Biophys. J."},{"key":"10.1016\/j.addr.2016.02.001_bb0255","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.bpj.2013.12.027","article-title":"Ion-induced defect permeation of lipid membranes","volume":"106","author":"Vorobyov","year":"2014","journal-title":"Biophys. J."},{"key":"10.1016\/j.addr.2016.02.001_bb0260","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/srep01949","article-title":"Defined lipid analogues induce transient channels to facilitate drug-membrane traversal and circumvent cancer therapy resistance","volume":"3","author":"van Hell","year":"2013","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2016.02.001_bb0265","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3109\/00498254.2012.751140","article-title":"The limited intestinal absorption via paracellular pathway is responsible for the low oral bioavailability of doxorubicin","volume":"43","author":"Kim","year":"2013","journal-title":"Xenobiotica"},{"key":"10.1016\/j.addr.2016.02.001_bb0270","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1529\/biophysj.105.060871","article-title":"Permeation of aromatic carboxylic acids across lipid bilayers: the pH-partition hypothesis revisited","volume":"89","author":"Thomae","year":"2005","journal-title":"Biophys. J."},{"key":"10.1016\/j.addr.2016.02.001_bb0275","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1021\/es5003428","article-title":"Role of tetracycline speciation in the bioavailability to Escherichia coli for uptake and expression of antibiotic resistance","volume":"48","author":"Zhang","year":"2014","journal-title":"Environ. Sci. Technol."},{"key":"10.1016\/j.addr.2016.02.001_bb0280","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s11095-007-9263-y","article-title":"Comparing the lipid membrane affinity and permeation of drug-like acids: the intriguing effects of cholesterol and charged lipids","volume":"24","author":"Thomae","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2016.02.001_bb0285","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1002\/cbdv.200900122","article-title":"Lipid-bilayer permeation of drug-like compounds","volume":"6","author":"Kr\u00e4mer","year":"2009","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.addr.2016.02.001_bb0290","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1021\/mp100050d","article-title":"Enabling the intestinal absorption of highly polar antiviral agents: ion-pair facilitated membrane permeation of zanamivir heptyl ester and guanidino oseltamivir","volume":"7","author":"Miller","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2016.02.001_bb0295","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1021\/jm9704311","article-title":"Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist","volume":"41","author":"Pagliara","year":"1998","journal-title":"J. Med. Chem."},{"issue":"Pt 11","key":"10.1016\/j.addr.2016.02.001_bb0300","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1107\/S0108270100010349","article-title":"Tetracycline hydrochloride: a synchrotron microcrystal study","volume":"56","author":"Clegg","year":"2000","journal-title":"Acta Crystallogr. C"},{"key":"10.1016\/j.addr.2016.02.001_bb0305","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1365-2125.1984.tb02500.x","article-title":"Comparative bioavailability of tetracycline and lymecycline","volume":"18","author":"Sjolin-Forsberg","year":"1984","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.addr.2016.02.001_bb0310","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1021\/js980181r","article-title":"Importance of tautomers in the chemical behavior of tetracyclinesdagger","volume":"88","author":"Duarte","year":"1999","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2016.02.001_bb0315","unstructured":"S.D. Kr\u00e4mer, http:\/\/www.biopharmacy.ethz.ch\/simulations.html."},{"issue":"Suppl. 1","key":"10.1016\/j.addr.2016.02.001_bb0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-4362.36.s1.2.x","article-title":"Bioavailability and pharmacokinetics of cyclosporine formulations: neoral vs sandimmune","volume":"36","author":"Choc","year":"1997","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.addr.2016.02.001_bb0325","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1002\/hlca.19900730703","article-title":"Reinvestigation of the conformation of cyclosporin A in chloroform","volume":"73","author":"Kessler","year":"1990","journal-title":"Helv. Chim. Acta"},{"key":"10.1016\/j.addr.2016.02.001_bb0330","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1021\/jm400887j","article-title":"Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties?","volume":"57","author":"Giordanetto","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2016.02.001_bb0335","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1021\/mp300564v","article-title":"Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue","volume":"10","author":"Gupta","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2016.02.001_bb0340","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.coph.2013.08.004","article-title":"Drug transport via the intestinal peptide transporter PepT1","volume":"13","author":"Brandsch","year":"2013","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.addr.2016.02.001_bb0345","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1016\/j.bmc.2015.06.022","article-title":"Intriguing possibilities and beneficial aspects of transporter-conscious drug design","volume":"23","author":"Tashima","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.addr.2016.02.001_bb0350","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1124\/dmd.114.060392","article-title":"Drug disposition and drug\u2013drug interaction data in 2013 FDA new drug applications: a systematic review","volume":"42","author":"Yu","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.addr.2016.02.001_bb0355","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1208\/s12248-013-9470-x","article-title":"Drug\u2013drug interaction studies: regulatory guidance and an industry perspective","volume":"15","author":"Prueksaritanont","year":"2013","journal-title":"AAPS J."},{"key":"10.1016\/j.addr.2016.02.001_bb0360","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.tips.2009.10.001","article-title":"The complexities of antiretroviral drug\u2013drug interactions: role of ABC and SLC transporters","volume":"31","author":"Kis","year":"2010","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.addr.2016.02.001_bb0365","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1517\/17425255.2014.884069","article-title":"Hepatobiliary transporters in drug-induced cholestasis: a perspective on the current identifying tools","volume":"10","author":"de Lima Toccafondo Vieira","year":"2014","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.addr.2016.02.001_bb0370","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s10354-014-0301-1","article-title":"Interplay of drug metabolizing enzymes with cellular transporters","volume":"164","author":"Bohmdorfer","year":"2014","journal-title":"Wien. Med. Wochenschr."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X16300515?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X16300515?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T13:36:08Z","timestamp":1567604168000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X16300515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":74,"alternative-id":["S0169409X16300515"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2016.02.001","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"When barriers ignore the \u201crule-of-five\u201d","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2016.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}